Chikungunya Vaccines

Chikungunya Vaccines 2024

Like many vaccines, Chikungunya virus (CHIKV) vaccine technologies, such as live-attenuated virus vaccines, inactivated viral vaccines, recombinant viral vaccines, chimeric-alphavirus candidates, DNA vaccines, and virus-like particles, focus on optimizing the balance between efficacy, immunogenicity, and safety, says the World Health Organization (WHO). On October 23, 2024, the U.S. CDC Advisory Committee on Immunization Practices reviewed Chikungunya vaccine presentations led by Edwin Asturias, M.D.

Chikungunya Vaccine Approved

Valneva SE's IXCHIQ® (VLA1553) chikungunya vaccine was approved by the U.S. in 2023 and in Canadia in 2024. The European Commission granted IXCHIQ marketing authorization in Europe in July 2024.

Chikungunya Vaccine Candidates 2024

The WHO says several advanced chikungunya vaccine candidates are approaching or undergoing regulatory review.

CHIKV-VLP is a CHIKV virus-like particle vaccine candidate produced by Bavarian Nordic A/S.

Bharat Biotech International Ltd's (BBIL) Chikungunya vaccine candidate (BBV87) is an inactivated whole virion vaccine candidate based on a strain derived from an East, Central, and South African genotype.

mRNA-1944 vaccine candidate encodes a fully human IgG antibody isolated initially from the B cells of a patient with a prior history of potent immunity against Chikungunya infection.

CD8+ T cell CHIKV Adaptive Vaccine candidate. Inclusion of the ligandome into the vaccine construct will require the selection of eight to twelve peptides from amongst the CHIKV peptide set (ligandome), all of which meet several specific criteria. In vitr, efficacy studies will then need to be completed.

The Access to Advanced Health Institute received an $18 million award from the National Institutes of Health to develop a temperature-stable, single-dose vaccine candidate for the chikungunya virus. The vaccine uses an innovative RNA platform technology.

A CHIKV vaccine candidate based on baculovirus displaying chikungunya virus E1-E2 envelope confers protection against challenge in mice. Immunization of C57BL/6 mice with non-adjuvanted recombinant baculovirus-induced IgG antibodies against E2 with a predominant IgG2c subtype, neutralizing antibodies, and a specific IFN-γ CD8+ T-cell response. Immunization with a second dose significantly boosted the antibody response.

U.S. CDC and Chikungunya Vaccines

At the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) on October 26, 2023, Dr. S Hills presented EtR and proposed policy options for chikungunya vaccine use among U.S. adults traveling abroad, and EtR and offered policy options for chikungunya vaccine use among laboratory workers. At the June 22, 2023, meeting, Nicole Lindsey, MS, presented the Value of a Vaccine to prevent travel-related chikungunya for U.S. persons. And Susan Hills, MBBS, MTH, presented WORK GROUP PLANS AND TIMELINES. The initial timeline indicates a potential CDC authorization in mid-2024. On February 23, 2023, ACIP presentations: Introduction, Dr. Beth Bell; Global epidemiology of Chikungunya, Dr. Susan Hills; Chikungunya in U.S. travelers, Ms. Nicole Lindsey; Persistent arthralgia following Chikungunya, Ms. Nicole Lindsey; Workgroup considerations, Ms. Nicole Lindsey. Previously on October 19, 2022, the ACIP reviewed the following presentations led by Beth Bell, MD, MPH Chair, ACIP Chikungunya Vaccines Work Group; OVERVIEW OF CHIKUNGUNYA AND CHIKUNGUNYA VACCINES; VLA1553 Chikungunya Vaccine Candidate; CDC WORKGROUP INTERPRETATION OF VACCINE DATA AND WORKGROUP PLANS AND TIMELINES. On June 23, 2022, the ACIP presentation by Dr. B Bell and Dr. S Hills: Overview of chikungunya and chikungunya vaccines; Plans and timeline for workgroup activities, offered relevant insights.

Chikungunya Vaccine Market

Market Research Future announced that the Chikungunya vaccine market is expected to register an annual growth rate of 10.12% from 2022 to 2032 and is estimated to reach $500 million in sales annually.